Medindia

X

MEDIA ALERT - Delivering On Our Public Health Commitment: An Update on A (H1N1) Vaccine Supply and Safety

Thursday, November 12, 2009 General News J E 4
Advertisement


/PRNewswire -- Nov. 10/

WHAT Sanofi-aventis CEO Chris Viehbacher and Sanofi Pasteur President & CEO Wayne Pisano will discuss how the company is meeting the challenges of manufacturing A (H1N1) vaccine. David Greenberg, M.D., Senior Director, Scientific and Medical Affairs, Sanofi Pasteur, will provide new data from adult and pediatric clinical trials of the U.S. licensed Influenza A (H1N1) 2009 Monovalent Vaccine. WHY Sanofi Pasteur, the largest company in the world devoted entirely to vaccines -- and the only company producing an inactivated influenza vaccine at a manufacturing facility located in the United States -- has worked closely with the U.S. Department of Health and Human Services and other public health agencies to develop and produce a safe A (H1N1) vaccine that provides a robust immune response. Sanofi Pasteur's U.S. facility has been operating 24 hours a day, seven days a week to produce A (H1N1) vaccine. WHEN 2:30 p.m. ET Wednesday, November 11, 2009 HOW To participate in this Webcast briefing, click on the following link to register and for further login instructions: http://www.visualwebcaster.com/event.asp?id=63928 Please Note: Participants should be sure to run a system check when registering to confirm system compatibility. To perform this check, click the link below the registration form. CONTACT For additional information: Freeman Miller Burson-Marsteller on behalf of Sanofi Pasteur 212-614-4216 Freeman.miller@bm.com

SOURCE Sanofi Pasteur
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
New Website Helps Families Lower, or Even Eliminat...
S
Stelara is Expected to Substantially Alter Patient...